HPV 검사 및 팹 테스트 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 제품별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

HPV Testing And Pap Test Market Summary

The global HPV testing and Pap test market size was estimated at USD 3.34 billion in 2024 and is projected to reach USD 6.18 billion by 2033, growing at a CAGR of 7.2% from 2025 to 2033. Technological advancements in testing products, increasing prevalence of cervical cancer, and government initiatives to reduce disease burden are some of the key factors driving the market growth over the forecast period.

Cervical cancer remains a critical health issue for women worldwide. In March 2024, the WHO published a fact sheet showing that approximately 660,000 women were diagnosed with cervical cancer in 2022, and about 350,000 women died from it. The highest incidence and mortality rates are found in low- and middle-income countries, particularly in sub-Saharan Africa, Central America, and Southeast Asia, where disparities in access to vaccination, screening, and treatment continue to drive this significant health burden.

Making screening and early detection must remain at the forefront of public health planning. At the root of much of this burden lies the human papillomavirus (HPV). A meta-analysis and systematic review published by the Technical University of Munich in January 2025 found that in women aged 50 and older with normal cytology, the pooled global prevalence of any HPV was 11.70% and the prevalence of high-risk HPV types was 6.45%. The high prevalence of HPV infection highlights the large population eligible for screening and emphasizes the critical role of HPV testing in cervical cancer prevention programs. Given that persistent HPV infection is the leading cause of cervical cancer, incorporating reliable HPV tests alongside Pap test is increasingly essential.

Favorable initiatives undertaken by governments for cervical cancer screening of women in the average-to-high-risk group are further anticipated to drive the market. Some of the guideline committees are ACS, the U.S. Preventive Services Task Force (USPSTF), the American Society for Colposcopy and Cervical Pathology (ASCCP), the American College of Obstetricians and Gynecologists (ACOG), and the Society of Gynecologic Oncology (SGO) is continuously increasing awareness about the disease among people. Moreover, in May 2023, the National Cervical Screening Program (NCSP) of Australia updated guidelines to prevent cervical cancer by increasing screening of women aged between 25 to 74 years.

An increase in awareness programs for screening by organizations including National Cervical Cancer Coalition (NCCC), WHO, CDC, and USPSTF is one of the major factors expected to boost market growth during the forecast period. For instance, in January 2023, the WHO launched the Cervical Cancer Elimination Strategy for the Eastern Mediterranean region and announced January as a Cervical Cancer Awareness month. Under this program, the WHO set the target to screen 70% of women aged 35 to 45 years. In addition, major market players are undertaking initiatives to increase awareness about cervical and vaginal cancer screening to detect diseases at an early stage.

The introduction of technologically advanced testing products and guidelines for utilizing novel tests is expected to further increase market growth over the forecast period. Market players are expanding their R&D activities to introduce novel and effective HPV tests for diagnosing infections. In March 2025, WHO prequalified the Alinity m HR HPV diagnostic test by Abbott, which detects DNA from 14 high-risk HPV genotypes, including genotypes 16, 18, and 45. The test's results, combined with clinical assessment and guidelines, can help guide patient management.

Global HPV Testing And Pap Test Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global HPV testing and Pap test market report based on type, application, product, technology, end use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Pap Test
• HPV Test
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Cervical Cancer Screening
• Vaginal Cancer Screening
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Consumables
• Services
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• PCR
• Immunodiagnostics
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Sweden
  • Denmark
  • Norway
  • Russia
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
  • Singapore
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. Product
  • 1.2.4. Technology
  • 1.2.5. End Use
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Application outlook
  • 2.2.3. Product outlook
  • 2.2.4. Technology outlook
  • 2.2.5. End Use outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. HPV Testing And Pap Test Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. HPV Testing And Pap Test Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. HPV Testing And Pap Test: Product Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. HPV Testing And Pap Test: Type Movement Analysis
• 4.3. Global HPV Testing And Pap Test Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.3.1. Pap Test
    • 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.3.2. HPV Test
    • 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. HPV Testing And Pap Test: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. HPV Testing And Pap Test: Application Movement Analysis
• 5.3. Global HPV Testing And Pap Test Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 5.3.1. Cervical Cancer Screening
    • 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.2. Vaginal Cancer Screening
    • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. HPV Testing And Pap Test: Product Estimates & Trend Analysis

• 6.1. Product Segment Dashboard
• 6.2. HPV Testing And Pap Test: Product Movement Analysis
• 6.3. Global HPV Testing And Pap Test Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 6.3.1. Instruments
    • 6.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.2. Consumables
    • 6.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.3. Services
    • 6.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. HPV Testing And Pap Test: Technology Estimates & Trend Analysis

• 7.1. Technology Segment Dashboard
• 7.2. HPV Testing And Pap Test: Technology Movement Analysis
• 7.3. Global HPV Testing And Pap Test Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 7.3.1. PCR
    • 7.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Immunodiagnostics
    • 7.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.3. Others
    • 7.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. HPV Testing And Pap Test: End Use Estimates & Trend Analysis

• 8.1. End Use Segment Dashboard
• 8.2. HPV Testing And Pap Test: End Use Movement Analysis
• 8.3. Global HPV Testing And Pap Test Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 8.3.1. Hospitals & Clinics
    • 8.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.2. Laboratories
    • 8.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.3. Others
    • 8.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. HPV Testing And Pap Test: Regional Estimates & Trend Analysis

• 9.1. Regional Market Dashboard
• 9.2. Regional Market Share Analysis, 2021 & 2033
• 9.3. HPV Testing and Pap Test by Region: Key Takeaways
• 9.4. North America
  • 9.4.1. U.S.
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework/ reimbursement structure
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.2. Canada
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/ reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.3. Mexico
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/ reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 9.5. Europe
  • 9.5.1. UK
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.2. Germany
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.3. France
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.4. Italy
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/ reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.5. Spain
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework/ reimbursement structure
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.6. Sweden
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework/ reimbursement structure
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.7. Denmark
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Regulatory framework/ reimbursement structure
    • 9.5.7.3. Competitive scenario
    • 9.5.7.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.8. Norway
    • 9.5.8.1. Key country dynamics
    • 9.5.8.2. Regulatory framework/ reimbursement structure
    • 9.5.8.3. Competitive scenario
    • 9.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.9. Russia
    • 9.5.9.1. Key country dynamics
    • 9.5.9.2. Regulatory framework/ reimbursement structure
    • 9.5.9.3. Competitive scenario
    • 9.5.9.4. Russia market estimates and forecasts 2021 to 2033 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. China
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.2. India
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.3. Japan
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/ reimbursement structure
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.4. Australia
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/ reimbursement structure
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.5. South Korea
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/ reimbursement structure
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.6. Thailand
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/ reimbursement structure
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.7. Singapore
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/ reimbursement structure
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Singapore market estimates and forecasts 2021 to 2033 (USD Million)
• 9.7. Latin America
  • 9.7.1. Brazil
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.2. Argentina
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 9.8. MEA
  • 9.8.1. South Africa
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework/ reimbursement structure
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.8.2. Saudi Arabia
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/ reimbursement structure
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.8.3. UAE
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework/ reimbursement structure
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.8.4. Kuwait
    • 9.8.4.1. Key country dynamics
    • 9.8.4.2. Regulatory framework/ reimbursement structure
    • 9.8.4.3. Competitive scenario
    • 9.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. Key company heat map analysis, 2024
• 10.4. Company Profiles
  • 10.4.1. Abbott.
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. QIAGEN
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. BD.
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Quest Diagnostics Incorporated
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Hologic, Inc.
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. F. Hoffmann-La Roche Ltd
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Femasys Inc.
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Arbor Vita Corporation
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. NURX Inc.
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Seegene Inc.
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives
  • 10.4.11. Thermo Fisher Scientific Inc.
    • 10.4.11.1. Company overview
    • 10.4.11.2. Financial performance
    • 10.4.11.3. Product benchmarking
    • 10.4.11.4. Strategic initiatives
  • 10.4.12. BIOMERIEUX S.A.
    • 10.4.12.1. Company overview
    • 10.4.12.2. Financial performance
    • 10.4.12.3. Product benchmarking
    • 10.4.12.4. Strategic initiative